trending Market Intelligence /marketintelligence/en/news-insights/trending/wg5nk4-h2sy63hdh1bl6pg2 content esgSubNav
In This List

Coherus Biosciences board member steps down

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Coherus Biosciences board member steps down

Redwood City, Calif.-based Coherus Biosciences Inc. said August Troendle resigned from the company's board.

In order to balance the membership among the company's three director classes following Troendle's resignation, V. Bryan Lawlis was reclassified as a class 1 director from class 2 director previously.

Lawlis' reappointment decreases the number of Coherus' authorized directors from eight to seven.

Coherus Biosciences develops biosimilars for treating arthritis, cancers and other diseases. The company noted that Troendle's resignation was not as a result of any disagreement.